1) The clinical spectrum of Caspr2-antibody associated disease2) What’s Trending: Interview with Lenore Launer about how hostile attitudes and effortful coping in young adulthood can predict cognition in later life 3) Topic of the month: Neurology Today story about five mentally stimulating activities associated with a lower risk for mild cognitive impairmentThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeremy Lanford interviews Dr. Maarten Titulaer about his paper on the clinical spectrum of Caspr2-antibody associated disease. Dr. Ted Burns is interviewing Dr. Lenore Launer for our “What’s Trending” feature of the week about her paper on how hostile attitudes and effortful coping in young adulthood can predict cognition in later life. Dr. Ted Burns interviews Drs. Janina Krell-Roesch and Gregg Day about a Neurology Today story on the topic of five mentally stimulating activities associated with a lower risk for mild cognitive impairment.DISCLOSURES: Dr. Titulaer serves on the scientific advisory board for MedImmune; serves as an editorial board member for Neurology®: Neuroimmunology & Neuroinflammation; received funding for travel from Sun Pharma; receives research support from Netherlands Organization for Scientific Research, Dutch Epilepsy Foundations and ErasmusMC fellowship.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Launer receives research support from the National Institute on Aging Intramural Research Program.Dr. Day received funding for travel from Pfizer, Canada for Future Leader in Dementia award; receives Research support from Avid Pharmaceuticals, American Brain Foundation, Clinical Research Training Fellowship, Eugene M Johnson Jr, Weston Brain Institute Postdoctoral Fellowship; and holds stock options in ANI Pharmaceuticals (2014-2015).